Companies › Sclnow Biotechnology
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Infectious disease, Other, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SCLnow 19# (Human umbilical cord mesenchymal stem cells) Autologous/allogeneic mesenchymal stem cell therapy administered via intraarticular inject | – | Phase 2 | Osteoarthritis, Knee | Dec 2026 |
| human umbilical cord mesenchymal stem cells (19#iSCLife®-LDP) Human umbilical cord mesenchymal stem cell therapy | – | Phase 1 | Lumbar Discogenic Pain; Hepatitis B | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04104412 | human umbilical cord mesenchymal stem cells (19#iSCLife®-LDP) | Phase 1 | Lumbar Discogenic Pain | Other | Dec 2026 |
| NCT03826433 | human umbilical cord mesenchymal stem cells (19#iSCLife®-LDP) | Phase 1 | Hepatitis B | Infectious disease | Dec 2026 |
| NCT03383081 | SCLnow 19# (Human umbilical cord mesenchymal stem cells) | Phase 2 | Osteoarthritis, Knee | Immunology | Dec 2026 |
No annotated target.
–
InventVacc Biologicals Medipost Aimei Vacin BioPharm (Zhejiang) Sirnaomics Changchun BCHT Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.